Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
Chairmen's Foreword: beta-blockade across the cardiovascular continuum—when and where to use?
1 Department of Cardiology, Lund University and Heart Health Group, Geijersg, 55, S-216 19, Malmö, Sweden
2 Department of Internal Medicine III, University of Cologne, D-50937 Cologne, Germany
* Corresponding author. Tel: +46 40 36 46 36, Fax: +46 40 36 46 34, Email: rw@hhgab.com
| The first 10% of the full text of this article appears below. |
Beta-blockade across the cardiovascular continuum: when and where to use? was the title of a satellite symposium held on 1 September 2008, during the annual congress of the European Society of Cardiology (ESC) in Munich, Germany, and sponsored by Merck Serono. The term cardiovascular continuum was first coined by Dzau and Braunwald in 1991 to describe a new paradigm for cardiovascular diseases.1 The concept of a continuum is based on the idea that cardiovascular conditions such as angina pectoris, myocardial infarction